Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Outset Medical reports robust Q4 performance and eyes home market growth

Outset Medical's Q4 performance showcased strong growth in Tablo Consoles and revenue, with a focus on expanding home dialysis programs and improving patient experience.
The company's strategic initiatives to manage expenses, reduce inventory levels, and enhance cash flow position it for sustainable growth and operational efficiency.
Challenges lie in meeting revenue guidance, sustaining margin expansion, and optimizing sales force efficiency, while opportunities exist in expanding home programs and leveraging partnerships for growth.
Overall, Outset Medical's performance reflects a balanced approach to growth, operational excellence, and strategic positioning in the dialysis market.

Outset Medical excels in Q1 2023, eyes home dialysis growth

Outset Medical's Q1 2023 performance was robust, with revenue growth and margin expansion surpassing expectations.
The company's focus on innovation, margin improvement, and market expansion positions it well for sustained growth.
Challenges in managing expenses and cash burn require attention, but opportunities in home dialysis and premium offerings offer avenues for future growth.

Outset Medical reports strong Q2 results, eyes sustained growth

Outset Medical delivered robust Q2 2023 results, focusing on revenue growth, margin improvement, and commercial progress in acute and home markets. The company reiterated its revenue guidance for 2023 and expressed confidence in Q4 growth driven by business visibility and network effects.
Despite facing challenges related to FDA compliance and market expansion, Outset Medical showcased strengths in customer base expansion, service margin improvement, and market acceptance of Tablo. The company's commitment to patient and provider autonomy underpins its dedication to delivering quality healthcare solutions.
With opportunities to present economic analysis data, drive utilization in acute care settings, and capitalize on Tablo's value proposition, Outset Medical is poised for sustained growth in 2024. Leveraging market trends and addressing challenges will be key to the company's success in the evolving healthcare landscape.

Outset Medical reports Q3 growth, eyes strategic expansion opportunities

Outset Medical's Q3 performance reflects steady revenue growth and margin expansion, with a focus on strategic growth initiatives.
The company's strengths lie in Tablo's success in both acute and home markets, positioning it for future growth and market expansion.
Challenges include navigating competitive pressures and achieving profitability amidst evolving market dynamics, while opportunities exist in market penetration and strategic growth avenues.

Outset Medical reports strong Q4 earnings, eyes growth opportunities

Outset Medical's Q4 performance was strong, with revenue meeting expectations and showing growth, driven by recurring revenue and expense reductions.
The company's strengths lie in wide market presence, valuable software offerings, unique technology, and effective competitive response strategies.
Challenges include deepening patient census, competitive pressures, transitioning to home dialysis, and maintaining cost efficiency and quality of care.
Opportunities for Outset Medical include revenue growth through software, the shift towards home dialysis, Medicare Advantage support, and payer discussions.

Outset Medical reports Q1 revenue miss, focuses on profitability goals

Outset Medical's Q1 performance showed progress despite revenue challenges, with a focus on cost reduction and profitability.
Strengths lie in successful partnerships, nationwide coverage, and gross margin improvement.
Challenges include revenue impact from delays and the need to balance restructuring with customer experience.
Opportunities include revenue growth in Q2, pipeline expansion, and leveraging technology advantage for innovation.

Outset Medical faces sales transformation challenges amidst revenue softness

Outset Medical's Q2 2024 earnings call highlighted revenue softness from console sales but strength in treatment sales and gross margin performance. The company is undergoing a sales transformation to target mainstream enterprise adopters and expects revenue of approximately $110 million for the year.

Outset Medical reports robust Q3 results and eyes growth opportunities

Outset Medical's Q3 performance showcased revenue growth, margin expansion, and strategic focus on profitability.
While facing challenges in maintaining margins, the company remains optimistic about growth opportunities in various market segments.
Executives highlighted the importance of a conservative outlook and emphasized the strength of their order pipeline and sales transformation progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Outset Medical Inc Shareholders Are Asked To Participate In The Securities Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Outset Medical Inc Investors Are Encouraged To Join The Securities Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Outset Medical Inc Investors Encouraged To Participate In Securities Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Have Opportunity To Participate In Outset Medical Inc Securities Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Outset Medical, Inc. ("Outset Medical") (NASDAQ:OM) concerning possible violations of federal securities laws. Outset Medical reported its second-quarter financial results on August 7, 2024, revealing a notable decrease in revenue and a downward adjustment in its full-year guidance.

Lost Money on Outset Medical, Inc. (OM)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Outset Medical, Inc. ("Outset Medical") (NASDAQ:OM) concerning possible violations of federal securities laws. Outset Medical reported its second-quarter financial results on August 7, 2024, revealing a notable decrease in revenue and a downward adjustment in its full-year guidance.

Lost Money on Outset Medical, Inc.(OM)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Shareholder Rights Advocates at Levi & Korsinsky Investigate Outset Medical, Inc. (OM) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / August 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Outset Medical, Inc. ("Outset Medical") (NASDAQ:OM) concerning possible violations of federal securities laws. Outset Medical reported its second-quarter financial results on August 7, 2024, revealing a notable decrease in revenue and a downward adjustment in its full-year guidance.

Outset Medical, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - OM

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) on behalf of Outset stockholders. Our investigation concerns whether Outset has violated the federal securities laws and/or engaged in other unlawful business practices.

OUTSET ALERT: Bragar Eagel & Squire, P.C. is Investigating Outset Medical, Inc. on Behalf of Outset Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

OM Investors Can Join Outset Medical, Inc. Securities Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Outset Medical, Inc. ("Outset Medical") (NASDAQ:OM) concerning possible violations of federal securities laws. Outset Medical reported its second-quarter financial results on August 7, 2024, revealing a notable decrease in revenue and a downward adjustment in its full-year guidance.

Shareholders that Lost Money on Outset Medical, Inc. (OM) Should Contact Levi & Korsinsky About Securities Fraud Investigation - OM

LOS ANGELES , Aug. 9, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

OM Investors Have Opportunity to Join Outset Medical, Inc. Securities Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Outset investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit yo.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Outset Medical, Inc. (OM) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) investors concerning the Company's possible violations of federal securities laws. On August 7, 2024, Outset Medical released its second quarter 2024 financial results, significantly missing consensus estimates and lowering its full year 2024 outlook. The Company stated that the “changes [it] needs to make are entirely in [.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Outset Medical, Inc. (OM) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 7, 2024, Outset Medical released its second quarter 2024 financial results, significantly missing consensus estimates and lowering its full year 2024 outloo.

The Law Offices of Frank R. Cruz Continues Its Investigation of Outset Medical, Inc. (OM) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Outset Medical, Inc. ("Outset Medical") (NASDAQ:OM) concerning possible violations of federal securities laws. Outset Medical reported its second-quarter financial results on August 7, 2024, revealing a notable decrease in revenue and a downward adjustment in its full-year guidance.

Levi & Korsinsky Announces an Investigation on Behalf of Outset Medical, Inc. (OM) Shareholders Who May Have Been Affected by Fraud

Outset Medical reported mixed Q2 2024 results, with improved profitability but lower-than-expected revenue.

Outset Medical Sees Profit Growth, Revenue Dip

Outset Medical (NASDAQ: OM ) stock is taking a beating on Thursday after the medical technology company announced earnings results for the second quarter of the year. The Outset Medical earnings report starts with an adjusted EPS of -47 cents.

Why Is Outset Medical (OM) Stock Down 34% Today?

Outset Medical, Inc. (NASDAQ:OM ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Jim Mazzola - Head, Investor Relations Leslie Trigg - Chair & Chief Executive Officer Nabeel Ahmed - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Rick Wise - Stifel Shagun Sing - RBC Capital Markets Suraj Kalia - Oppenheimer Kristen Stewart - CL King Stephanie Piazzola - Bank of America Securities Drew Ranieri - Morgan Stanley Josh Jennings - TD Cowen Operator Ladies and gentlemen, thank you for standing by. Welcome to Outset Medical Second Quarter 2024 Earnings Conference Call.

Outset Medical, Inc. (OM) Q2 2024 Earnings Call Transcript

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.69 per share a year ago.

Outset Medical, Inc. (OM) Reports Q2 Loss, Misses Revenue Estimates

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2024. “During the quarter, the number of treatments performed each month on Tablo continued at record levels, as utilization remained high and gross margin materially expanded as it has each quarter for more than.

Outset Medical Reports Second Quarter 2024 Financial Results

Outset Medical (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Outset Medical, Inc. (OM) Report Negative Earnings Next Week? What You Should Know

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, August 7, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Offic.

Outset Medical to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

Abbott Labs

Inmode Ltd

Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one.

3 MedTech Stocks to Buy for Healthy Gains

Outset Medical (OM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News for Outset Medical Stock (OM)